Effects of insulin resistance and testosterone on the participation of cyclooxygenase isoforms in vascular reactivity

Harish Vasudevan 1
Sally Lau 1
Jihong Jiang 2
John H McNeill 1

1Division of Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada; 2Pediatric Oncology, Children and Women’s Hospital, Child and Family Research Institute, Vancouver, British Columbia, Canada

Abstract: Testosterone plays an important role in mediating hypertension and altered vascular reactivity associated with insulin resistance. In addition to other pathways, testosterone-dependent changes in aortic cyclooxygenase (COX-2) mRNA levels affect blood pressure following insulin resistance. However, their effects on vascular tone are unclear. We studied the changes in contraction response to phenylephrine (PE) in the aorta and superior mesenteric artery (SMA) from intact and gonadectomized fructose-fed rats. Constriction response to PE was studied in tissues incubated with the COX-1 and COX-2-selective antagonists, SC-560 and NS-398, respectively, and indomethacin, in addition to assessing its role in endothelium-dependent relaxation. Finally, changes in COX-2 protein expression and plasma thromboxane A2 (TXA2), a downstream vasoconstrictor metabolite of COX-2, were measured. In fructose-fed rats, castration prevented the increase in blood pressure but not insulin resistance. The involvement of COX-2 in mediating the alpha-adrenergic vasoconstriction was higher in intact rat aorta compared to COX-1, which was prevented by castration. However, in the SMA, COX-2 participation was dependent on testosterone alone. Fructose-induced attenuation of endothelial relaxation was restored by indomethacin, which suggests a pro-vasoconstrictor role for COX. Both diet and testosterone did not alter vascular COX-2 expression thus suggesting the involvement of downstream testosterone-dependent pathways. This is supported by increased plasma TXA2 in the castrated rats compared to intact rats. Isoform-specific actions of COX are tissue-selective in states of insulin resistance and involve potential testosterone-dependent downstream targets. Further studies are needed to investigate the role of androgens and insulin resistance in vascular arachidonic acid metabolism.

Keywords: insulin resistance, cyclooxygenase, testosterone, vascular reactivity, phenylephrine

Introduction

The role of insulin resistance in the induction of cardiovascular complications has been extensively studied. Resistance to insulin is associated with secondary complications such as endothelial dysfunction and impaired vasorelaxation, which leads to hypertension. We have previously demonstrated these effects in fructose-fed rats, a diet-induced model of the metabolic syndrome. Insulin resistance impairs the endothelium-dependent relaxation in superior mesenteric arteries, which is dependent on nitric oxide (NO). The development of endothelial dysfunction and elevated blood pressure is also dependent on the presence of testosterone. Testosterone replacement reverses the beneficial effects of castration to elevate the blood pressure, which is similar to that observed in intact fructose-fed rats. Although testosterone has been associated with upregulating several pro-constrictor pathways such as the renin–angiotensin system (RAS) and
COX-1 and COX-2 to PE-induced vasoconstriction in the relaxation, 2) to identify the individual contributions of the effect of COX inhibition on endothelium-dependent responses to PE following angiotensin receptor blockade. 

Cyclooxygenase (COX) and testosterone have been demonstrated to influence vascular reactivity in long-term sucrose-fed rats. However so far only COX-2 expression has been shown to be elevated in the aorta of fructose-fed rats. Currently, sparse information is available regarding the roles of COX-1 and COX-2 in mediating agonist-induced vasoreactivity.

Vasoactive prostanoids such as prostaglandins, 8-isoprostane, and thromboxane A2 (TXA2) are downstream metabolites of COX-1 and COX-2 action or arachidonic acid. Of the two COX isoforms, COX-2 has been implicated to have a greater influence on vascular tone as selective COX-2 inhibition attenuates responses to phenylephrine (PE) in the aortas of spontaneously hypertensive rats. In fructose-fed rats, following insulin resistance, elevations in both aortic COX-2 expression and TXA2 were observed. Selective inhibition of COX-2 in fructose-fed rats by celecoxib and nimesulide not only inhibited TXA2 and 8-isoprostane formation but also improved insulin sensitivity and decreased the blood pressure. These results implicate COX-2 as a key player in the development of insulin resistance and a subsequent increase in blood pressure.

In addition to a direct effect on insulin sensitivity and blood pressure, COX may also be an important downstream mediator of agonist-induced vasoconstriction. This is demonstrated by the involvement of COX in the attenuated responses to PE following angiotensin receptor blockade. In addition, Puyo et al. have reported altered prostanoid levels in the mesenteric bed of fructose-fed rats in the presence of angiotensin-II and noradrenaline. COX is also a downstream target of endothelin-1 (ET-1), which has been implicated in mediating cardiovascular complications secondary to insulin resistance. Interestingly, recent evidence has demonstrated crosstalk between ET-1 and the RAS secondary to insulin resistance. Thus it may be possible that in an insulin-resistant milieu, both isoform-specific and/or non-specific COX-dependent mechanisms may contribute to PE-induced vasoconstriction. Currently, there are no functional data to demonstrate the specific contributions of individual COX isoforms in that maintenance of vascular tone.

In this study, we had 3 main objectives: 1) to examine the effect of COX inhibition on endothelium-dependent relaxation, 2) to identify the individual contributions of COX-1 and COX-2 to PE-induced vasoconstriction in the superior mesenteric artery (SMA) and aorta of normal and fructose-fed rats, and 3) to determine whether testosterone affects the regulation of vascular reactivity by COX.

**Materials and methods**

Sixty-four male Wistar rats were obtained from Charles River, Montreal, Canada. Thirty-two rats had their testes surgically removed at the age of 5 weeks while the remaining 32 were sham-operated at the same age prior to shipment. The rats were maintained under regular light/dark cycle with ad libitum access to food and water. The rats were acclimated for 1 week in the animal facility at the Faculty of Pharmaceutical Sciences, University of British Columbia and cared for in accordance with the guidelines outlined by the Canadian Council on Animal Care (CCAC). The protocol for animal use was approved by the Animal Care Committee of the University of British Columbia. In each study, the starch in normal laboratory rat chow was replaced in 50% of animals with a diet enriched with fructose (60%), which was obtained commercially as a preformulated diet (Teklad Labs, Madison, WI). This high-fructose containing diet has been shown in previous studies to induce insulin resistance and hypertension. The rats in the control groups (C and G) were fed standard laboratory rat chow.

**Experimental design**

In both studies rats were divided into 4 groups, sham-operated normal chow-fed control (C; n = 8), sham-operated fructose-fed (F; n = 8), gonadectomized normal chow-fed (G; n = 8), and gonadectomized-fructose-fed (GF; n = 8).

Following 9 weeks of fructose feeding, an oral glucose tolerance test was performed on the rats as previously described. At termination, the rats were euthanized by a single injection of 65 mg/kg intraperitoneal injection of pentobarbital followed by opening of the chest cavity. Blood was collected by cardiac puncture for determination of plasma testosterone and TXA2 levels. In study 1, the SMA was isolated and cleaned of excess adipose and connective tissues for measuring changes in vascular reactivity. In study 2, both SMA and thoracic aorta were isolated for vascular reactivity experiments.

**Measurement of blood pressure and assessment of insulin resistance/sensitivity**

Systolic blood pressure was measured in conscious rats prior to the start of and after 9 weeks of fructose feeding using the indirect noninvasive tail-cuff method as previously described.
Insulin sensitivity was calculated following the oral glucose challenge using the formula of Matsuda and DeFronzo using 100 as constant: ISI = 100/square root of [(fasting glucose × fasting insulin) × (mean glucose × mean insulin)].

**Studies on vascular reactivity**

**Study 1**

Endothelium-intact tissue rings each of length 3 to 4 mm were dissected from the SMA and appended onto glass hooks, which were then mounted in a 20 mL isolated tissue bath containing oxygenated (95% O₂ and 5% CO₂) Krebs Ringer buffer at 37°C as described previously. Following an initial challenge with 40 mM potassium chloride (KCl), changes in endothelium-dependent relaxation were assessed in the isolated SMA. Briefly, relaxation to increasing doses of acetylcholine (ACh) (10⁻⁹–10⁻³ M) was determined in tissues precontracted with the ED₅₀ dose of PE. The vessels were then incubated with 10⁻⁵ M indomethacin for 20 minutes and the above-described procedure was repeated. Results are reported as percentage relaxation of contraction produced by PE.

**Study 2**

Following assessment of endothelial integrity in the presence of 1 µM ACh, the aorta and SMA were assessed for changes in contractile responses to increasing concentrations of PE (10⁻⁶–10⁻³ M), in the absence and presence of the following drugs: 1) a selective COX-2 inhibitor (NS-398; 10⁻⁶ M), 2) a selective COX-1 inhibitor (SC-560; 10⁻⁶ M, and 3) a non-selective COX inhibitor (indomethacin; 10⁻⁶ M). NS-398 has been shown to exhibit a 100-fold greater selectivity to COX-2 over COX-1. Similarly SC-560 selectively inhibits COX-1 as the IC₅₀ values are 1000-fold higher than those for COX-2. Our aim was to individually inhibit COX-2 and COX-1 followed by total blockade with indomethacin to provide an insight into the role played by each isoform in vascular reactivity.

Briefly, following the challenge with 40 mM KCl and confirmation of endothelial integrity, a basal cumulative response curve to PE was obtained. Post equilibration, the tissues were incubated individually with NS-398 (10⁻⁶ M) followed by SC-560 (10⁻⁵ M) and indomethacin (10⁻⁵ M) (in that order) for 20 minutes each. For example, after obtaining responses to PE in the presence of NS-398, the tissues were washed with Krebs Ringer until the contraction returned to baseline values. Upon equilibration, they were then treated with SC-560 and the process was repeated for both SC-560 and indomethacin. Additionally, a second ring from the same tissue was used as a time control.

At the end of the experiment, the tissues were blotted onto KimWipes® (Kimberley-Clark, Irving, TX) and weighed. Responses to PE were reported as mg/mm² tension in the SMA and as percentage of maximum KCl contraction in the aorta.

**COX-2 protein expression**

Protein levels of COX-2 in the tissues were evaluated by Western blotting based on previously reports from our laboratory using rabbit polyclonal antibodies against COX-2 (Abcam, MA and Cell Signaling, Danvers, MA). Briefly protein lysates were prepared by homogenizing tissues in RIPA buffer. The proteins, with concentrations of 0.5 to 1 µg/µL/sample, were separated by electrophoresis and transferred onto PVDF membranes. Following blocking with 5% nonfat milk, the membranes were incubated overnight at 4°C with 1:5000 COX-2 antibody in BSA (bovine serum albumin-fraction 5 (Roche Diagnostics, QC, Canada). The membranes were then washed with TBS-T and incubated with horseradish peroxidase (HRP)-conjugated anti-rabbit secondary antibody (1:10,000 in 5% nonfat milk) at room temperature for 1 hour. Following 3 × 10-minute washings with TBS-T, the membranes were developed in ECL reagent (ECL reagent A&B; GE Life Sciences, QC, Canada). A monoclonal mouse antibody (1:2000; Abcam, MA) was used to determine glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression, which was used as control.

Changes in band densities were recorded using ImageJ™ software. Sample band densities were normalized to their corresponding GAPDH band density to obtain a ratio. These values were in turn expressed relative to control (C), ie, assuming each C value to be 1.

**Biochemical parameters**

Glucose was measured in the plasma using a Beckman glucose analyzer. Insulin was measured using radioimmunoassay kits from Linco, MO. Testosterone was measured in the plasma using a commercially available radioimmunoassay kit from MP Biomedicals (Solon, OH). Thromboxane B2 (TXB₂), the stable metabolite of TXA₂, was measured in the plasma using an EIA kit (GE Life Sciences).

**Chemicals and reagents**

All chemicals unless otherwise mentioned were of reagent grade and purchased from Sigma (St Louis, MO). Phenylephrine and acetylcholine were dissolved in Krebs Ringer while NS-398 and SC-560 were dissolved in dimethyl sulfoxide.
(DMSO). Indomethacin was dissolved in 10% sodium bicarbonate (Na₂CO₃) solution. 20 µL of each drug solution was added to the bath during the study.

**Statistical analysis**

All data were analyzed using one-way analysis of variance (ANOVA). Data involving multiple time points were subject to the general linear model (GLM) ANOVA using the NCSS 2000™ statistical software (NCSS, Kaysville, UT). The Newman–Keuls test was used as a post hoc test. The value of $P < 0.05$ was taken as the level of significance. All results are reported as mean ± SEM.

**Results**

Statistical analysis of insulin sensitivity, plasma testosterone, and blood pressure showed no significant differences between the two studies. Therefore, we have combined the data from both studies and presented the values in a single table (Table 1).

Similar to previous reports from our laboratory, fructose decreased the insulin sensitivity as demonstrated by the decrease in insulin sensitivity index values in the fructose-fed rats (F and GF) (Table 1).

Blood pressure was elevated in sham-operated fructose-fed rats at the end of 9 weeks (F, 134 ± 2 mmHg vs C, 113 ± 2 mmHg; $P < 0.05$). Fructose did not affect the blood pressure in gonadectomized animals (GF, 113 ± 2 mmHg) (Table 1).

Testosterone was undetectable in gonadectomized rats. Fructose did not affect testosterone levels (Table 1).

**Vascular reactivity studies**

**Acetylcholine response**

Similar to previous reports from our laboratory, fructose feeding attenuated the relaxation to ACh in F but not in GF, suggesting the prevention of endothelial dysfunction in the absence of testosterone (Figure 1A and 1B). Inhibition of COX by indomethacin ameliorated the relaxation to ACh in the SMA of intact fructose-fed rats. Indomethacin did not affect the relaxation in other groups as analyzed by 2-way ANOVA (Figure 2).

**Phenylephrine response**

In this experiment, contractile responses to PE over time did not change in the control vessels corresponding to treated vessels.

**Superior mesenteric artery**

Endothelium-intact vessels were used for these experiments. In the absence of inhibitors, responses to PE were unchanged in both intact and gonadectomized fructose-fed rats (Figure 3A).

Treatment with NS-398 attenuated the PE-induced vasoconstriction in both control and fructose-fed rats with

![Figure 1](https://www.dovepress.com/)

**Table 1** Insulin sensitivity index, systolic blood pressure, and plasma testosterone in rats following fructose feeding

<table>
<thead>
<tr>
<th>Groups</th>
<th>Insulin sensitivity index (ng/mL)</th>
<th>Systolic blood pressure (mmHg)</th>
<th>Plasma testosterone (ng/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>C</td>
<td>12.0 ± 0.8</td>
<td>113 ± 2</td>
<td>2.2 ± 0.4</td>
</tr>
<tr>
<td>F</td>
<td>8.3 ± 0.8*</td>
<td>134 ± 2*</td>
<td>2.0 ± 0.2</td>
</tr>
<tr>
<td>G</td>
<td>15.2 ± 1.0</td>
<td>110 ± 1</td>
<td>&lt;LLQ</td>
</tr>
<tr>
<td>GF</td>
<td>9.5 ± 0.8*</td>
<td>113 ± 2</td>
<td>&lt;LLQ</td>
</tr>
</tbody>
</table>

Notes: The 4 experimental groups were control (C), fructose-fed (F), gonadectomized (G), and gonadectomized fructose-fed (GF). Values are presented as mean ± SEM. Statistical analysis was done by one-way ANOVA followed by Newman–Keuls post hoc test. $P < 0.05$ F and GF vs C and G; $P < 0.05$ F vs C, G, and GF. Abbreviation: <LLQ, not detected as below limit of quantitation.

**Figure 1** Fructose feeding attenuated the relaxation to acetylcholine in the superior mesenteric artery, which is prevented by gonadectomy. A) Relaxation responses were obtained to acetylcholine (ACh, $10^{-9}$–$10^{-4}$ mol/L) after precontraction with ED₇₀ phenylephrine in the 4 experimental groups: control (C), fructose-fed (F), gonadectomized (G), and gonadectomized fructose-fed (GF). B) Shows area under the curve (AUC) values for the responses. Notes: * indicates significant differences ($P < 0.05$) compared with other groups.
intact testes as compared to the gonadectomized groups. Although there was no statistical significance observed in Figure 3B, the area under the curve values showed a difference between G and GF vs C and F (Table 2).

No statistical differences were observed in the contractile responses to PE following incubation with indomethacin (Figure 3C). However, in comparison with untreated controls, indomethacin attenuated the contraction to PE. Similar to NS-398, indomethacin did not affect the responses to PE in G and GF (G + INM: 18547 ± 4282 and GF + INM: 21210 ± 6537). This suggests the presence of a testosterone-dependent involvement of COX. In addition, the data point to selective COX-2 involvement in mediating physiological responses to PE.

Treatment with SC-560, the selective COX-1 blocker, did not affect PE-induced vasoconstriction in any of the groups (Figure 3D). This suggests a lack of involvement for COX-1 in PE-induced constriction.

COX inhibition did not affect the pD2 values in tissues (Table 2). However, the changes in maximum concentration values (Rmax) mirrored the drug-dependent changes observed in the concentration response curves to PE discussed earlier (Table 2).

Aorta
Similar to the SMA, fructose feeding did not affect the responses to PE in isolated aorta (Figure 4A). In the presence of NS-398, PE-evoked contraction was unaffected in all groups except F (Figure 4B). NS-398 decreased the responses in F compared to basal values but not in C, suggesting insulin resistance may be responsible for the augmented dependence on COX-2 in aorta (Table 3). COX-2 dependent modulation of constriction was absent in the gonadectomized rats where the degree of attenuation of PE-induced vasoconstriction was greater in F as compared to GF (Figure 4B).

Indomethacin produced a contraction pattern similar to that observed in presence of NS-398. Therefore while indomethacin did not affect the responses in C, contraction to PE was attenuated in intact fructose-fed rats. Tissues from G and GF were unaffected by the presence of indomethacin (Figure 4C). Similar to NS-398, PE-induced contraction was significantly lower only in F following indomethacin treatment (Table 3).

Responses to PE were unaffected in all groups following selective COX-1 blockade (Figure 4D). Further SC-560 did not affect the responses compared to basal values in any of the groups. This is similar to the results observed in SMA.

Similar to the SMA, pD2 values were unaffected in all groups. However, inhibition of COX attenuated the Rmax values in F but not C, G and GF (Table 3).

COX-2 protein expression
In both the aorta and SMA, fructose and gonadectomy did not affect COX-2 expression (Figure 5A and 5B, respectively).

Plasma TXB2 levels
Levels of TXB2, the stable metabolite of TXA2, were the highest in gonadectomized fructose-fed rats as compared to other groups. Fructose feeding also slightly elevated the TXB2 in intact rats compared to controls (Figure 6).

Discussion
In the present study, in addition to confirming the effects of fructose diet and testosterone on insulin resistance and blood pressure, we report for the first time that in the presence of testosterone, insulin resistance increases the individual participation of COX-2 in mediating vasoconstriction to PE in the aorta. However, in this study, there was no change in the aortic COX-2 expression, which is not in agreement with previous reports from our laboratory.4,17 In the current study, rats were fed with fructose for 9 weeks, which was similar to the protocol by Jiang et al17 but was longer than the duration of fructose feeding in Song et al.4 While we are unable to explain this variation, one possibility would be to examine...
COX-2 expression in aortas incubated with PE. This would mimic the milieu present when we investigate the changes in vascular reactivity and help us confirm the effects of insulin resistance on the contributions of COX in mediating α-adrenoceptor-stimulated vasoconstriction.

The availability of isoform-selective inhibitors of COX enabled us to look at the individual contributions of COX-1 and COX-2 to the vasculature. Thus, although COX-2 expression was unchanged (Figure 5A and 5B), both insulin resistance and testosterone promote the increased involvement of COX-2 in mediating vasoconstriction to PE in the aorta (Figure 4A–D; Table 3). Our findings are partly supported by Martorell et al who have shown improved relaxation to ACh in gonadectomized rat aorta along with concomitant increase in COX-2 expression and function.30

In the SMA, COX-2 may be regulated by testosterone alone and not by diet (Figure 3A–D; Table 2). COX-2 expression was unchanged in the SMA of intact and gonadectomized rats, which was similar to that observed following treatment with the androgen receptor blocker flutamide.31 Furthermore, the improvement in endothelium-dependent relaxation upon COX inhibition (Figure 2) suggests a role in attenuating vasodilation and not in promoting vasoconstriction in the SMA of fructose-fed rats.

Although the degree of COX involvement is altered following insulin resistance, neither insulin resistance nor testosterone affected basal PE-induced contraction in both the aorta and SMA of F compared to controls (C) (Figures 3A and 4A respectively). This is in agreement with previous work from our laboratory.3,32 While separate studies have shown upregulation in other vasoconstrictor systems such as endothelin-1,33,34 RAS,9,22 and sympathetic nervous systems35–37 along with parallel attenuation in NO and endothelium-dependent hyperpolarizing factor-dependent relaxation,3,38 the responses to a vasoconstrictor such as PE are unchanged in intact fructose-fed rats. In control intact and gonadectomized rat vessels, achievement of homeostasis may be attributed to a robust endothelial NO-dependent

---

**Figure 3** Contractile responses to phenylephrine (PE) in the superior mesenteric arteries (SMA) of intact and gonadectomized control and fructose-fed rats in the presence and absence of inhibitors. The 4 experimental groups were control (C), fructose-fed (F), gonadectomized (g), and gonadectomized fructose-fed (GF). A) Contractile responses to PE (10⁻⁹–10⁻⁴ mol/L) were unchanged in the absence of inhibitors. B) COX-2 selective inhibition by NS-398 (10⁻⁶ M) attenuated the responses to PE (10⁻⁹–10⁻⁴ mol/L) in the SMA of intact (C and F) but not in gonadectomized (g and GF) rats. *P < 0.05 g and GF vs C and F. C) Responses to PE (10⁻⁹–10⁻⁴ mol/L) were unaffected in the presence of the nonselective COX isoform inhibitor indomethacin (10⁻⁵ M). Both fructose and gonadectomy did not affect responses to PE subsequent to incubation with indomethacin. D) Responses to PE (10⁻⁹–10⁻⁴ mol/L) were unchanged in both intact and gonadectomized control and fructose-fed rats following incubation with the COX-1 selective inhibitor SC-560 (10⁻⁵ M). Values are in terms of mg/mm². "n" values are indicated on the graph. All values are presented as mean ± SEM.
Table 2 Area under the curve (AUC for contraction response to phenylephrine [PE]) values, potency (pD2) values, and maximum contraction values (R\text{max}) to PE in the superior mesenteric artery

<table>
<thead>
<tr>
<th>Groups</th>
<th>AUC (Basal)</th>
<th>PE + NS-398</th>
<th>PE + SC-560</th>
<th>PE + INM</th>
<th>pD2 (Basal)</th>
<th>PE + NS-398</th>
<th>PE + SC-560</th>
<th>PE + INM</th>
<th>R\text{max} (Basal)</th>
<th>PE + NS-398</th>
<th>PE + SC-560</th>
<th>PE + INM</th>
</tr>
</thead>
<tbody>
<tr>
<td>C</td>
<td>15784 ± 897</td>
<td>8928 ± 2193</td>
<td>10427 ± 1958</td>
<td>7865 ± 2043</td>
<td>6.5 ± 0.2</td>
<td>6.0 ± 0.2</td>
<td>6.1 ± 0.2</td>
<td>6.0 ± 0.4</td>
<td>6463 ± 397*</td>
<td>3916 ± 772</td>
<td>4589 ± 561</td>
<td>3850 ± 546*</td>
</tr>
<tr>
<td>F</td>
<td>19223 ± 1832</td>
<td>8006 ± 360*</td>
<td>13554 ± 2848</td>
<td>10224 ± 1827*</td>
<td>6.7 ± 0.2</td>
<td>6.1 ± 0.2</td>
<td>6.3 ± 0.3</td>
<td>6.5 ± 0.3</td>
<td>7148 ± 417*</td>
<td>3879 ± 313*</td>
<td>5825 ± 920</td>
<td>4897 ± 817*</td>
</tr>
<tr>
<td>G</td>
<td>11345 ± 4936</td>
<td>18509 ± 2264</td>
<td>11528 ± 2345</td>
<td>18547 ± 4282</td>
<td>6.6 ± 0.4</td>
<td>6.7 ± 0.2</td>
<td>6.2 ± 0.2</td>
<td>6.4 ± 0.4</td>
<td>4876 ± 1673</td>
<td>4311 ± 1404</td>
<td>3991 ± 712</td>
<td>6722 ± 1863</td>
</tr>
<tr>
<td>GF</td>
<td>30856 ± 7048</td>
<td>24871 ± 5733</td>
<td>20300 ± 4624</td>
<td>21210 ± 6537</td>
<td>6.9 ± 0.3</td>
<td>6.4 ± 0.2</td>
<td>6.4 ± 0.3</td>
<td>6.3 ± 0.3</td>
<td>10325 ± 1844</td>
<td>9839 ± 2031*</td>
<td>8321 ± 1037</td>
<td>8527 ± 1819</td>
</tr>
</tbody>
</table>

Notes: Pressor responses to phenylephrine (PE) were evaluated in control (C, n = 5–7), fructose-fed (F, n = 4–7), gonadectomized (G, n = 5–6), and fructose-fed in selective (NS-398 and SC-560) and nonselective indomethacin (INM) inhibition of COX-1 and -2. All values are presented as mean ± SEM. *P < 0.05 PE + NS-398 and PE + INM vs PE (Basal). †P < 0.05 GF vs C, F and G (all PE + NS-398).

Pathways such as the levels of the cytochrome P450 4A (CYP4A) catalyzed arachidonic acid metabolite, 20-HETE, in cultured rat vascular smooth muscle cells.44–47 Additional testosterone increases TXA2 receptor density and expression in cultured rat vascular smooth muscle cells.48–49 This may be contrary to in vitro data, which show that testosterone increases TXA2 receptor levels in cultured rat vascular smooth muscle cells.48–49 Additional experiments are needed to tease out whether TXA2 synthesis and/or action is testosterone dependent.

Oxidative stress associated with the metabolic syndrome has been shown to increase the synthesis of vasoactive agents such as TXA2 (Figure 6) and eicosanoids,43 which may not be salutary to the overall hemodynamics of the vasculature.41 Interestingly, both oxidative stress and angiotensin-II COX-2 in the signaling pathways involved in PE-induced vasoconstriction may be neutralized by NO thus achieving homeostasis.

Therefore, we speculate that endothelium-independent mechanisms may be involved in preventing exaggerated vasoconstriction responses to PE. These pathways because had COX-2 stimulated TXA2 synthesis, may not be salutary to the overall hemodynamics of the vasculature. An increase in oxidative stress is involved in induced endothelium-independent pathway present in the vascular reactivity. In principle, the potential increase in oxidative stress due to insulin resistance is accounted for the testosterone-dependent differences in vasomotor reactivity. The potential increase in oxidative stress due to insulin resistance is accounted for the testosterone-dependent differences in vasomotor reactivity. It would also be interesting to study the potential interactions of COX-2 with other testosterone-dependent pathways such as the RAS16 and COX-2. It would also be interesting to study the potential interactions of COX-2 with other testosterone-dependent pathways such as the RAS16 and COX-2. It would also be interesting to study the potential interactions of COX-2 with other testosterone-dependent pathways such as the RAS16 and COX-2.
and RAS. Thus, although the effects of these systems have been investigated individually, sparse information exists about any interplay among these systems. We believe that the testosterone-dependent COX-2, RAS, and Cyp4A pathways could be interrelated and together contribute to endothelial dysfunction and hypertension.

In conclusion, the present work supports our earlier hypothesis that the vasoactive imbalance associated with endothelial dysfunction leads to attenuated endothelium-dependent relaxation and not elevated vasoconstriction. This is reflected in animal models of type 2 diabetes, such as Otsuka Long-Evans Tokushima fatty rats, where attenuated endothelial relaxation was ameliorated by blocking COX. Although individual vasoconstrictors may have been elevated subsequent to insulin resistance, their effects could be masked by endothelium-independent vasorelaxant pathways, which are activated as a compensatory mechanism. An important factor to consider is the time-dependent changes in contraction response to PE as the tissues were treated with various individual inhibitors over time. In the absence of COX inhibitors, the control tissues showed no change in contraction to PE over time, which indicates the responses to be consistent and reliable. COX-2 is selectively recruited in mediating vasoconstriction to PE and this phenomenon is regulated by testosterone. Inhibiting COX attenuates the synthesis of vasoconstrictor prostanoids thereby improving relaxation. This phenomenon, however, is tissue selective as the participation of COX in mediating contractile responses to PE following insulin resistance is elevated only in the aorta whereas in the SMA it is independent of diet. These findings warrant further study in order to identify the specific position of COX-catalyzed prostanoids in individual vasculature in addition to supporting the salutary effects of COX-2 inhibition in vivo in insulin resistance. Identifying molecular players in this phenomenon would contribute to a better understanding of the diverse vasoactive processes that are triggered by prostanoids.

Figure 4 Contractile responses to phenylephrine (PE) in the aorta of intact and gonadectomized control and fructose-fed rats in the presence and absence of inhibitors. The 4 experimental groups were control and intact (C), fructose-fed (F), gonadectomized (G), and gonadectomized fructose-fed (GF). A) Contractile responses to PE ($10^{-10}$–$10^{-4}$ mol/L) were unchanged in the absence of inhibitors. B) COX-2 selective inhibition by NS-398 ($10^{-6}$ M) attenuated the responses to PE ($10^{-9}$–$10^{-4}$ mol/L) in the aorta of intact (C and F) but not in gonadectomized (G and GF) rats. *$P < 0.05$ G and GF vs C and F. C) Isoform nonselective COX inhibition by indomethacin ($10^{-5}$ M) attenuated the responses to PE ($10^{-8}$ to $10^{-4}$ mol/L) in intact (C and F) but not in gonadectomized (G and GF) rat aorta. *$P < 0.05$ G and GF vs C and F. D) Responses to PE ($10^{-9}$–$10^{-4}$ mol/L) were unchanged in both intact and gonadectomized control and fructose-fed rat aorta in the presence of the selective COX-1 inhibitor, SC-560 ($10^{-5}$ M). Values are in terms of % maximum response to KCl. "n" values are indicated on the graph. All values are presented as mean ± SEM.
Acknowledgments

We would like to thank Violet Yuen for her assistance in the project and in preparing this manuscript. This project was funded by grants-in-aid from The Heart and Stroke Foundation of BC and Yukon (HSFBCY) and Canadian Institutes of Health Research (CIHR).

Table 3 Area under the curve (AUC for contraction response to phenylephrine [PE]) values, potency (pD2) values, and maximum contraction values (Rmax) to PE in the aorta

<table>
<thead>
<tr>
<th>Groups</th>
<th>AUC PE (Basal)</th>
<th>PE + NS-398</th>
<th>PE + SC-560</th>
<th>PE + INM</th>
<th>pD2 PE (Basal)</th>
<th>PE + NS-398</th>
<th>PE + SC-560</th>
<th>PE + INM</th>
<th>Rmax PE (Basal)</th>
<th>PE + NS-398</th>
<th>PE + SC-560</th>
<th>PE + INM</th>
</tr>
</thead>
<tbody>
<tr>
<td>C</td>
<td>375 ± 40</td>
<td>208 ± 43</td>
<td>329 ± 92</td>
<td>276 ± 92</td>
<td>7.1 ± 0.14</td>
<td>6.5 ± 0.14</td>
<td>6.6 ± 0.21</td>
<td>6.7 ± 0.21</td>
<td>122 ± 9</td>
<td>82 ± 13</td>
<td>107 ± 26</td>
<td>101 ± 29</td>
</tr>
<tr>
<td>F</td>
<td>370 ± 49</td>
<td>129 ± 29*</td>
<td>293 ± 103</td>
<td>91 ± 15*</td>
<td>6.9 ± 0.14</td>
<td>6.9 ± 0.40</td>
<td>6.6 ± 0.20</td>
<td>6.3 ± 0.41</td>
<td>127 ± 12</td>
<td>44 ± 10*</td>
<td>106 ± 34</td>
<td>40 ± 10*</td>
</tr>
<tr>
<td>G</td>
<td>415 ± 43</td>
<td>359 ± 47</td>
<td>272 ± 20</td>
<td>346 ± 79</td>
<td>7.3 ± 0.14</td>
<td>6.7 ± 0.13</td>
<td>6.7 ± 0.07</td>
<td>6.5 ± 0.023</td>
<td>130 ± 11</td>
<td>111 ± 12</td>
<td>102 ± 5</td>
<td>130 ± 24</td>
</tr>
<tr>
<td>GF</td>
<td>386 ± 48</td>
<td>388 ± 85</td>
<td>309 ± 28</td>
<td>424 ± 108</td>
<td>6.9 ± 0.20</td>
<td>6.8 ± 0.27</td>
<td>6.4 ± 0.24</td>
<td>6.5 ± 0.39</td>
<td>129 ± 12</td>
<td>131 ± 22</td>
<td>125 ± 10</td>
<td>175 ± 40</td>
</tr>
</tbody>
</table>

Notes: Pressor responses to PE were evaluated in control (C, n = 4–8), fructose-fed (F, n = 4–8), gonadectomized (G, n = 4–8), and gonadectomy fructose-fed (GF, n = 4–6) subsequent to selective (NS-398 and SC-560) and nonselective indomethacin (INM) inhibition of COX-1 and -2. All values are presented as mean ± SEM. *P < 0.05 PE + NS-398 and PE + INM vs PE (Basal) and PE + SC-560. †P < 0.05 F vs G and GF.

Figure 5 A) COX-2 expression was unchanged by fructose feeding in the aorta of intact and gonadectomized rats. The 4 experimental groups were control and intact (C), fructose-fed (F), gonadectomized (G), and gonadectomy fructose-fed (GF). COX-2 expression was normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH), which was used as the housekeeping protein. All groups n = 6. All values are presented as mean ± SEM. B) COX-2 expression in the superior mesenteric artery was unchanged by fructose feeding in intact and gonadectomized rats. Groups C, F, G, GF. COX-2 expression was normalized to GAPDH, which was used as the housekeeping protein. All groups n = 6. All values are presented as mean ± SEM.
Health Research (CIHR-Priority announcement grant from the Institute of Gender and Health) to Dr. McNeill. Harish Vasudevan was funded by a Doctoral Research Award from the Heart and Stroke Foundation of Canada and a Senior Graduate Studentship from the Michael Smith Foundation for Health Research British Columbia, Canada.

Disclosure
The authors declare no conflicts of interest.

References


